Prophylactic cefixime and prulifloxacin are effective in preventing acute bacterial sepsis after transrectal ultrasound-guided prostate biopsy, according to findings from a new trial presented at the 34th Annual European Association of Urology Congress in Barcelona this month.
For the trial, 120 patients aged 51-87 (mean 68.6) years and with a prostate-specific antigen value of 5.08-100 (mean 13.86) ng/mL were prospectively divided into two groups of 60 patients. Group A received a three-day regimen of cefixime 400 mg p.o/day, while group B received three days of prulifloxacin 600 mg p.o/day. Treatment commenced a day before the procedure and patients were followed up for symptoms for seven days post-biopsy.
Sixteen of the men had previously underwent a biopsy, while 18 patients had received prulifloxacine and eight had received cefixime at least once in the last three months.
During follow-up, 97.5 per cent of patients did not present with urinary tract infection post-biopsy.
Hospital admission because of septicaemia was required in 1.2 per cent of patients in group B and 0.6 per cent of patients in group A. The bacteria detected in these urine cultures were resistant to prulifloxacin and cefixime, while a history of use was noticed.